A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–Positive Breast CancerSara M. Tolaney, Carey K. Anders, PierFranco Conte et al.|Clinical Cancer Research|2020Cited by 204
A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2- metastatic breast cancer (MBC).Carey K. Anders, Sara M. Tolaney, Émilie Le Rhun et al.|Journal of Clinical Oncology|2019Cited by 39
Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–positive Breast CancerSara M. Tolaney, Carey K. Anders, Solmaz Sahebjam et al.|Clinical Cancer Research|2021Cited by 4
eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer.Sara M. Tolaney, Shom Goel, Lesley Fallowfield et al.|Journal of Clinical Oncology|2021Cited by 1